CORRECTION Open Access



Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Andreas R. Gantenbein^{1*}, Reto Agosti², Christian P. Kamm^{3,4}, Gunther Landmann⁵, Niklaus Meier⁶, Gabriele Susanne Merki-Feld⁷, Jens A. Petersen⁸, Heiko Pohl⁹, Philippe Ryvlin¹⁰, Christoph J. Schankin³, Dragana Viceic¹¹, Chiara Zecca^{12,13}, Elisabeth Schäfer¹, Ina Meyer¹⁴ and Michael E. Arzt¹⁴

Correction: J Headache Pain 23, 142 (2022) https://doi.org/10.1186/s10194-022-01515-8

Following publication of the original article [1], the author group has identified an error in Fig. 1. The correct figure is given below.

The original article [1] has been corrected.

Author details

¹Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland. ²Kopfwehzentrum Hirslanden, Zurich, Switzerland. ³Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland. ⁴Neurocentre, Luzerner Kantonsspital, Lucerne, Switzerland. ⁵Center for Pain Medicine, Nottwil, Switzerland. ⁶Department of Neurology, Spital Thun, Thun, Switzerland. ⁷Department of Reproductive Endocrinology, University Hospital Zurich, Zurich, Switzerland. ⁸Neurozentrum Bern, Bern, Switzerland. ⁹Department of Neurology, University Hospital Zurich, Switzerland. ¹⁰Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland. ¹¹Private Practice, Sion, Switzerland. ¹²Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. ¹³Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland. ¹⁴Novartis Pharma Schweiz AG, Rotkreuz, Switzerland.

Published online: 19 December 2022

The original article can be found online at https://doi.org/10.1186/s10194-022-01515-8.

*Correspondence: andreas.gantenbein@zurzachcare.ch

Full list of author information is available at the end of the article



Reference

 Gantenbein AR, Agosti R, Kamm CP et al (2022) Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. J Headache Pain 23:142. https://doi.org/10.1186/s10194-022-01515-8

at the end of the article

© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.

© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wist http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

¹ Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland

